Diagnostic Tests/Kits Products & Reviews

The LumiraDx CRP Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify CRP levels in whole blood and plasma. Used with the LumiraDx Platform, the Test delivers rapid, quantitative results in 4 minutes at the point of care.

The LumiraDx D-Dimer Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify D-Dimer levels in whole blood and plasma. It is the only direct fingerstick D-Dimer assay available today*, aiding healthcare professionals to exclude deep vein thrombosis (DVT) and pulmonary embolism (PE) in symptomatic patients with confidence** - in only 6 minutes.

The LumiraDx HbA1c test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify HbA1c in fingerstick and venous whole blood. Used with the LumiraDx Platform, the LumiraDx HbA1c test delivers rapid, reliable results in approximately < 7 minutes at the point of care.

The LumiraDx NT-proBNP test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify NT-proBNP in human capillary and venous whole blood and plasma samples (Lithium Heparin). Used with the LumiraDx Platform, the LumiraDx NT-proBNP test delivers rapid, reliable results in 12 minutes at the point of care.

The LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.

The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens from individuals suspected of COVID-19 or asymptomatic individuals. Used with the LumiraDx Platform the test delivers rapid results at the point of care.

Lab-comparable results in just 5 minutes - With excellent performance and results in just 5 minutes, the LumiraDx SARS-CoV-2 Ag Ultra test enables you to accurately and confidently test more patients, optimize clinic workflows and help triage patients without delay

The LumiraDx SARS-CoV-2 Ag Pool Test is a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to 5 individuals suspected of COVID-19 or up to 5 asymptomatic individuals. Used with the LumiraDx Platform the test offers a rapid, scalable and cost-effective screening solution for infectious individuals.

Enzyme Immunoassay for the quantitative determination of Anti-Infliximab antibodies in human serum and plasma.

Is it COVID-19? Is it Flu? Lab-comparable results in minutes. Verify potential infection quickly with a rapid microfluidic assay that provides actionable and lab-comparable results in 12 mins for patients suspected of Flu and/or COVID-19, to help decision making and guide treatment.

Is it RSV? Is it COVID-19? Actionable results in minutes. Verify potential infection and help guide infection control measures quickly with a rapid microfluidic assay that provides actionable results in 12 minutes, for patients suspected of RSV and/or COVID-19.

Accurately quantitate immunosuppressive drug levels in human whole blood samples with MassTrak Immunosuppressant Calibrator, Quality Control, and Internal Standard sets.

Our unique combination of custom antibody development, lateral flow  development and manufacturing services, signal enhancement technology and our mobile diagnostic platform are shaping the future of lateral flow. Our partnership approach allows you to work with one company to reach your assay goals.

BBI Solutions’ Novarum™ technology transforms a smartphone into a mobile diagnostic platform, empowering users to read and share the results of rapid tests at the point of care.  

High sensitivity, specificity, and accuracy

Approved by ANSM in France

Confirm and Differentiate HIV-1 and HIV-2

Fully automated system

in vitro detection of antibodies to HIV-1 and HIV-2

Approved by Health Authorities in many European Countries

Detection of both current and past infection with H. pylori

Target Sufficiency® is the ability of a target system to respond to a therapeutic. It reflects the abundance and forms of the drug target protein, as well as other key system proteins that connect the target to disease phenotypes and enable response. Assessment of the target system requires an analysis platform that can simultaneously capture multiple precise protein measurements.

Gyrolab® Generic Cyno ADA Kit Reagents enable detection of anti-drug antibodies of human IgG or Fab in cynomolgus monkey matrix.

The InviRapid ® lateral flow test strips provide a fast and easy detection of diverse allergens within just a few minutes. These assays are suitable for on-site analysis, and do not require any laboratory equipment. They are user-friendly, even for inexperienced personnel, and can be applied in all stages of the food production process - from testing raw materials to finished good samples, and as part of the surface cleaning…

Opal 6-Plex Detection Kits - for Whole Slide Imaging (formerly Opal Polaris 7 Color IHC Detection Kits)